'Runaway train': Drug launch prices have grown 20% annually for more than a decade, and it's time for Congress to act, researchers say High tides: Long-term data ready Takeda for bringing first dengue travel vaccine to market Tempus ties up Eli Lilly collab to bring free genomic testing to lung cancer patients After months of warnings, CMS hands out its first fines to hospitals failing on price transparency Can biosimilars tear down AbbVie's Humira rebate wall? Just look at Viatris' Lantus copy: analyst Lawmakers introduce bill criminalizing violence, threats against hospital employees Alnylam stays on Calliditas’ heels as Regeneron-partnered nephropathy drug passes phase 2 GSK unveils new branding and logo to showcase 'transformed' business Abbott’s TriClip cuts heart valve leaks among patients with pacemakers Back in the Frame: CureVac inks biotech buyout to step up cancer vaccine R&D Foundation Medicine's tumor test scores yet another companion diagnostic nod, for Genentech's Rozlytrek ASCO: Takeda Oncology ready to stoke partnerships to fire up cancer-fighting pillar technologies UnitedHealth to invest $100M in diversifying healthcare workforce Featured Story | By Eric Sagonowsky With plenty of U.S. residents having to make tough financial decisions daily because of inflation, a new study confirms what many have likely been feeling for years: Drug prices are much, much higher than in the past. read more |
| |
|---|
|
Top Stories By James Waldron New long-term data from Takeda’s TIDES study of its dengue fever vaccine provide the missing piece of the puzzle in the Japanese pharma’s quest to bring the first travel shot for the infection to market. read more By Andrea Park Tempus fugit, but the Chicago medtech of the same name is aiming to stop the clock on cancer with its genomic sequencing tests. read more By Dave Muoio Northside Hospital Atlanta and Northside Hospital Cherokee ignored CMS' warnings and requests for corrective action since last fall, the agency said. They now face hundreds of thousands of dollars in fines. read more By Angus Liu AbbVie’s megablockbuster TNF blocker Humira is about to face biosimilars next year. But will those biosims succeed? According to analysts who examined Viatris and Biocon’s two biosimilar versions of Sanofi’s popular insulin Lantus, both high- and low-list-priced Humira copycats actually could steal market share. read more By Dave Muoio The bipartisan legislation is modeled after similar protections for airline workers and is backed by the American Hospital Association and American College of Emergency Physicians. read more By Max Bayer Alnylam has reached a phase 2 checkpoint of its Regeneron-partnered immunoglobulin A nephropathy treatment as it looks to catch up with Calliditas Therapeutics' FDA-approved med Tarpeyo. read more By Ben Adams As GlaxoSmithKline becomes GSK and sheds its consumer unit, the British Big Pharma has revealed new branding, a tech-flavored logo and a “transformative” change for its future. read more By Conor Hale For the first time, Abbott showed that its transcatheter clip-based therapy for the heart’s tricuspid valve could help stem leaks and improve quality of life specifically among patients who have received a pacemaker implant. read more By Nick Paul Taylor CureVac, bruised from its COVID-19 vaccine woes, has struck another deal to bolster its cancer vaccine development capabilities, buying Frame Cancer Therapeutics for its ability to identify unique and shared neoantigens. read more By Andrea Park Foundation Medicine’s flagship cancer diagnostic is designed to detect substitutions and alterations in more than 300 genes—and the company seemingly won’t rest until the test has been cleared for use alongside just as many cancer drugs. read more By Gabrielle Masson Takeda Oncology employees arrived on the scene at the American Society of Clinical Oncology meeting eager to be back in person and ready to talk potential partnerships that could bolster the Japanese pharma's three main “pillar” areas. read more By Paige Minemyer The United Health Foundation, the philanthropic arm of UnitedHealth Group, will invest $100 million over the next decade to drive a more diverse healthcare workforce. read more | 